Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. Curr Mol Med.

Ilie M, Benzaquen J, Hofman V, Lassalle S, Yazbeck N, Leroy S, Heeke S, Bence C, Mograbi B, Glaichenhaus N, Marquette CH, Hofman P.

2017;17(8):527-540.

Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients. Oncotarget.

Ilie M, Szafer-Glusman E, Hofman V, Long-Mira E, Suttmann R, Darbonne W, Butori C, Lalvée S, Fayada J, Selva E, Yu W, Marquette CH, Shames DS, Punnoose E, Hofman P. 

2017 Apr 18;8(16):26112-26121.

Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS One.

Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, Hofman P.

2017 Aug 10;12(8):e0183023.

Liquid biopsy for early detection of lung cancer. Curr Opin Oncol. 

Hofman P. 

2017 Jan;29(1):73-78.

PD-L1 expression in basaloid squamous cell lung carcinoma:
Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. Modern Pathology

Ilie M, Falk AT, Butori C, Chamorey E, Bonnetaud C, Long E, Lassalle S, Zahaf K, Vénissac N, Mouroux J, Cohen C, Brambilla E, Marquette CH, Hofman V, Hofman P.

2016 Dec;29(12):1552-1564

Pathologists and liquid biopsies: to be or not to be? Virchows Arch.

Hofman P, Popper HH. 

2016 Dec;469(6):601-609.

High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness. Cancer Med.

Long E, Ilie M, Bence C, Butori C, Selva E, Lalvée S, Bonnetaud C, Poissonnet G, Lacour JP, Bahadoran P, Brest P, Gilson E, Ballotti R, Hofman V, Hofman P. 

2016 Jun;5(6):1022-30.

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch

Ilie M, Hofman V, Dietel M, Soria JC, Hofman P.

2016 May;468(5):511-.

MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib. Oncotarget.

Lassalle S, Zangari J, Popa A, Ilie M, Hofman V, Long E, Patey M, Tissier F, Belléannée G, Trouette H, Catargi B, Peyrottes I, Sadoul JL, Bordone O, Bonnetaud C, Butori C, Bozec A, Guevara N, Santini J, Hénaoui IS, Lemaire G, Blanck O, Vielh P, Barbry P, Mari B, Brest P, Hofman P.

2016 May 24;7(21):30461-78.

Comparative study of the PDL1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol.

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, Mouroux J, Vénissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P.

2016 Jan;27(1):147-53.

Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. Cancer Res.
Hofman P, Cherfils-Vicini J, Bazin M, Ilie M, Juhel T, Hébuterne X, Gilson E, Schmid-Alliana A, Boyer O, Adriouch S, Vouret-Craviari V. 

2015 Mar 1;75(5):835-45.

Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. J Am Acad Dermatol.
Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, Bordone O, Gay A, Zahaf K, Poissonnet G, Lacour JP, Bahadoran P, Ballotti R, Gros A, Dutriaux C, Saiag P, Merlio JP, Vergier B, Emile JF, Hofman V, Hofman P.

2015 May;72(5):786-93

Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol.
Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, Marquette CH, Hofman P.

2015 Jan;26(1):238-44

Why and how immunohistochemistry should now be used to screen for
the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France). J Eur Acad Dermatol Venereol.

Long E, Ilie M, Lassalle S, Butori C, Poissonnet G, Washetine K, Mouroux J, Lespinet V, Lacour JP, Taly V, LaurentPuig P, Bahadoran P, Hofman V, Hofman P.

2015 Dec;29(12):2436-43.

Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer.
Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, Vénissac N, Sanfiorenzo C, Ferrua B, Marquette CH, Mouroux J, Hofman P.

2014 Mar 4;110(5):1236-43

Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls. Curr Mol Med.
Hofman V, Ilie M, Long E, Guibert N, Selva E, Washetine K, Mograbi B, Mouroux J, Vénissac N, Reverso-Meinietti J, Milano G, Mazières J, Marquette CH, Paterlini-Bréchot P, Hofman P.

2014 May;14(4):440-56

Public-private relationships in biobanking: a still underestimated key component of open innovation. Virchows Arch.
Hofman P, Bréchot C, Zatloukal K, Dagher G, Clément B. 

2014 Jan;464(1):3-9

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E
mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol.
Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper D, von Deimling A, Emile JF, Hofman P. 

2013 Mar;24(3):742-8.

Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation
in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol.
Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, Selva E, Tanga V, Passeron T, Poissonnet G, Emile JF, Lacour JP, Bahadoran P, Hofman P. 

2013 May;133(5):1378-81.

Two panels of plasmamicroRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One.
Sanfiorenzo C, Ilie MI, Belaid A, Barlési F, Mouroux J, Marquette CH, Brest P, Hofman P.

2013;8(1):e54596.